Effect of erigeron injection on platelet level of CD62p and serum content of TNF-alpha and IL-6 in patients with acute cerebral infarction.
- Author:
Jin-Liang WANG
1
;
Wei GU
;
Feng TAN
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Aged, 80 and over; Asteraceae; chemistry; Blood Platelets; metabolism; Cerebral Infarction; immunology; metabolism; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Injections; Interleukin-6; blood; Male; Middle Aged; P-Selectin; biosynthesis; blood; Phytotherapy; Tumor Necrosis Factor-alpha; metabolism
- From: Chinese Journal of Integrated Traditional and Western Medicine 2005;25(4):324-326
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical effect of Erigeron injection (El) on positive expression rate of CD62p in platelet and content of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in serum of patients with acute cerebral infarction (ACI).
METHODSSixty-eight patients with ACI were randomly divided into the treated group (n = 35) and the control group (n = 33). Conventional treatment were given to both groups, and EI 40 ml/d were given additionally to the treated group, the treatment course for both groups was 15 days. The positive expression of platelet CD62p and the serum TNF-alpha and IL-6 in patients before and after treatment were determined with flow cytometric (FCM) and electrochemical-luminescence (ECL) techniques respectively.
RESULTSThe total curative effect in the treated group were significantly higher than that in the control group (P < 0.05). Levels of platelet CD62p and serum TNF-alpha and IL-6 in ACI patients before and after treatment were significant higher than those in the healthy group (P < 0.05), all the three parameters were significantly decreased after treatment, and the lowering in the treated group was more significant than that in the control group (P < 0.05).
CONCLUSIONThe effect of El on ACI patients may relate to its action in down-regulating the expression of platelet CD62p, alleviating the immune response and inflammatory injury of central nervous system induced by cytokines.